Skip to main content

Time in Range

What's new

Time in Range Target

Major milestones in 2019 brought time in range to the forefront of diabetes care Continue Reading »

In-person visits, lab tests, and finger stick documentation are no longer required at present to get a CGM Continue Reading »

Expert physicians share a few of the benefits of virtual appointments for people living with diabetes Continue Reading »

Rybelsus, a GLP-1 agonist pill already approved in Europe and the US, has just been approved by Health Canada for adults with type 2 diabetes Continue Reading »

Dr. Diana Isaacs on improving time in range, making the most of your data, and the barriers facing people with diabetes and their healthcare teams Continue Reading »

Rybelsus, a GLP-1 agonist pill already approved in the US, received positive feedback from the European Medicines Agency (EMA) in January and was just approved on Saturday Continue Reading »

Mark Harmel, MPH, CDCES, discusses how his clinic is moving to telemedicine in the time of COVID-19 and how to share data from many diabetes devices Continue Reading »

The Time in Range Coalition aims to help millions of people by promoting time in range in diabetes care Continue Reading »

Pages